Omega-3 and Depression: What 26 Meta-Analyses Found

For years, the omega-3 and depression literature looked contradictory. Some meta-analyses found a meaningful benefit; others found none. The problem was that different trials used different doses, different omega-3 forms (EPA vs DHA), different patient groups, and different rating scales, and pooling all of them together blurred the signal. A 2019 meta-analysis by Liao and colleagues that synthesized 26 randomized controlled trials helped clarify the picture, and other recent reviews have largely agreed with it.

EPA vs. DHA: The Critical Distinction

The most important finding is that EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are not interchangeable for depression. EPA-dominant formulations — defined in the literature as containing at least about 60% EPA relative to total EPA+DHA — consistently outperform DHA-dominant or balanced products in antidepressant trials. Liao 2019 reported a moderate antidepressant effect for EPA-pure (SMD −0.61) and EPA-majority (≥60% EPA, SMD −0.51) formulations, while DHA-pure or DHA-majority products did not differ significantly from placebo.

DHA-only formulas showed no significant antidepressant effect across the pooled literature. Mixed EPA+DHA products fell in between, depending on the EPA fraction. This matters for anyone shopping for omega-3 supplements: a fish oil with 300 mg EPA and 200 mg DHA per capsule is a meaningfully different product than one with 200 mg EPA and 300 mg DHA, even though the total long-chain omega-3 content is identical.

Adjunctive Use Outperforms Monotherapy

Another finding consistent across reviews: omega-3 tends to work better as an add-on to antidepressants than as a stand-alone treatment. Trials testing EPA alongside SSRIs or SNRIs report larger effect sizes than trials testing EPA on its own. The mechanistic story behind this is that EPA appears to dampen low-grade inflammation and may modulate neuroplasticity — pathways that overlap with, but are distinct from, those targeted by conventional antidepressants.

The dose range in positive trials clusters around 1 to 2 g of EPA per day. Going above 3 g EPA per day has not produced additional benefit in trials, and at higher doses the antiplatelet effect of fish oil becomes more clinically relevant, especially for people on anticoagulants. Time also matters: most trials show effects emerging at 8 to 12 weeks of consistent use.

Who Benefits Most

Subgroup analyses consistently point to larger effects in: people with elevated inflammatory markers (high CRP or IL-6), those with cardiovascular risk factors, people with treatment-resistant depression, and those with very low baseline omega-3 intake (vegetarians, people who rarely eat oily fish). In people who already eat two or more servings of oily fish per week and have no inflammatory signal, the incremental benefit of a supplement is smaller.

The omega-3-and-depression story is one of the more mature supplement narratives in psychiatry. The question is no longer "does it work?" but "who benefits most, and under what conditions?" For EPA-dominant formulas in people with major depression — especially as augmentation to existing treatment — the answer is solid enough to be worth a clinical conversation.